 MAGNA intends to show that the combination of pseudoephedrine, chlorpheniramine, plus a small amount of belladonna alkaloid is a comprehensive, safe and effective twice daily BID drug treatment for seasonal allergic rhinitis SAR patients with post-nasal drip PND. The phase 1 single-dose trial will consist of 21 subjects: 1 to gather pharmacodynamic measurements and blood levels of active ingredients over 12 hours; 2 To report subjective scores by subjects rating efficacy of single dose of STAHIST; 3 To report any side effects or adverse drug reactions and rate the severity of incidence. 